Substance Name: Alefacept [USAN:INN:BAN]
RN: 222535-22-0
UNII: ELK3V90G6C
Notes
- A recombinant human fusion protein of LFA-3 antigen and immunoglobulin IGG1 that binds to CD2 ANTIGENS on memory T-LYMPHOCYTES, preventing their activation and proliferation. It is used in the management of moderate to severe chronic plaque PSORIASIS.
- Selectively targets activated memory-effector CD45RO T lymphocytes by binding to CD2. NK cells may mediate deletion of activated T cells.
Molecular Formula
- Unspecified
Classification Codes
- Dermatologic Agents
- Immunologic Factors
- Treatment of Autoimmune Diseases, Including Psoriasis and Transplant Rejection
- Treatment of Plaque Psoriasis
* denotes mobile formatted website
Links to Resources
NLM Resources (File Locators)
Other Resources (Internet Locators)
Names and Synonyms
Name of Substance
- Alefacept
- Alefacept [USAN:INN:BAN]
MeSH Heading
- Alefacept
Synonyms
- 1-92-Antigen LFA 3 (human) fusion protein with human immunoglobulin G 1 (hinge-CH2-CH3 gamma1-chain), dimer. Molecular weight is 36,235 to 36,837 daltons
- 1-92-LFA-3 (antigen) (human) fusion protein with immunoglobulin G1 (human hinge-CH2-Ch3 gamma1-chain), dimer
- Alefacept
- Amevive
- ASP 0485
- BG 9273
- BG 9712
- BG9273
- BG9712
- Human LFA 3IgG fusion protein
- LFA 3
- LFA 3CD2
- LFA 3TIP
- LFA3TIP
- UNII-ELK3V90G6C
Systematic Name
- 1-92-LFA-3 (antigen) (human) fusion protein with immunoglobulin G1 (human hinge-CH2-Ch3 gamma1-chain), dimer
Registry Numbers
CAS Registry Number
- 222535-22-0
FDA UNII
- ELK3V90G6C
System Generated Number
- 0222535220